Poolbeg Pharma PLC - London-based pharmaceutical company - Shares start trading on the OTCQB Venture Market in the US.

Chair Cathal Friel says: ‘We believe that having a US cross trading facility is important for the development of Poolbeg. It gives us the opportunity to widen our potential investor base, which we believe may help future liquidity, and capitalises on the interest in European stocks from US investor. In our view, OTCQB is a good complement to our AIM listing.

‘The OTC markets have expanded in recent years beyond pink sheet listings, and now include a premium market for companies such as Danone and Roche, and a venture market for companies of Poolbeg’s size.’

Current stock price: 6.50 pence, up 8.3% in London on Wednesday

12-month change: down 40%

Copyright 2022 Alliance News Limited. All Rights Reserved.